About Citryll

Citryll is taking a new approach to treat inflammatory diseases by inhibiting NETosis and the far-reaching pathogenic consequences of NETs rather than targeting a single mediator that participates in inflammation.

OUR TEAM
board of directors
Investors
Job Opportunities

Our science and products

Citryll’s lead asset, CIT-013, targets the release of NETs and their clearance. As a consequence, CIT-013 inhibits the build-up of pro-inflammatory enzymes and mediators, toxic histones and citrullinated autoantigens. Citryll’s program does so by interfering with formation, function and clearance of NETs and NET components.

With the ability to block NET release and promote the clearance of tissue NETs, CIT-013 is a transformative new treatment alternative for diseases with high medical need. Currently we focus our efforts on Rheumatoid Arthritis and Hidradenitis Suppurativa, but these may validate use in other inflammatory diseases where NETs show an important association with disease activity (e.g. ANCA vasculitis, Lupus, atherosclerosis, COPD and sepsis).

CIT-013, is currently progressing through clinical development, with Phase 2a studies in Rheumatoid Arthritis and Hidradenitis Suppurativa expected to begin later this year.

How it all started

Citryll was founded by the late Jos Raats, Helmuth van Es, and Renato Chirivi, CTO of Citryll. Citryll’s antibody development program results from the unexpected discovery, made by Jos and Renato, that therapeutic anti-citrullinated protein antibodies (ACPAs) from the immunoglobulin repertoire of rheumatoid arthritis patients had striking anti-inflammatory activity in animal models.